detrusitol retard 4 mg depotkapsler, hårde
upjohn eesv - tolterodintartrat - depotkapsler, hårde - 4 mg
dostinex 0,5 mg tabletter
pfizer aps - cabergolin - tabletter - 0,5 mg
estracyt 140 mg kapsler, hårde
pfizer aps - estramustinnatriumphosphat - kapsler, hårde - 140 mg
medrol 32 mg tabletter
pfizer aps - methylprednisolon - tabletter - 32 mg
rifabutin "pfizer" 150 mg kapsler, hårde
pfizer aps - rifabutin - kapsler, hårde - 150 mg
zavicefta
pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - antibakterielle midler til systemisk brug, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. det bør overvejes at officielle vejledning om hensigtsmæssig brug af antibakterielle midler..
provera 100 mg tabletter
pfizer aps - medroxyprogesteronacetat - tabletter - 100 mg
provera 5 mg tabletter
pfizer aps - medroxyprogesteronacetat - tabletter - 5 mg
palladia
zoetis belgium sa - toceranib - antineoplastiske midler - hunde - behandling af ikke-resekterbare patnaik grade ii (mellemklasse) eller -iii (højkvalitets), tilbagevendende, kutane mastcelletumorer hos hunde.
vfend
pfizer europe ma eeig - voriconazol - candidiasis; mycoses; aspergillosis - antimykotika til systemisk brug - voriconazol, er et bredt spektrum, triazol-svampemidler agent og er angivet i voksne og børn i alderen 2 år og derover, som følger:behandling af invasiv aspergillosis;behandling af i candidaemianon-neutropenic patienter, behandling af fluconazol-resistente alvorlige invasive candida infektioner (herunder c. krusei);behandling af alvorlige svampeinfektioner forårsaget af scedosporium spp.. og fusarium spp.. vfend bør administreres primært til patienter med progressive, eventuelt livstruende infektioner. profylakse af invasive svampeinfektioner i høj risiko allogen hæmatopoietisk stamcelletransplantation (hsct) modtagere.